Micron Biomedical

10:45 AM - 11:00 AM (EDT), Wednesday, June 7, 2023 ・ Session Room 103
Micron Biomedical is a clinical stage company developing products that utilize a proprietary microarray vaccine and drug delivery technology (MAP). Originally developed in Dr. Prausnitz labs at Georgia Tech. Self-Administration and/or less skilled caregiver administration of vaccines and drugs. No pain, no sharps, no cold chain are some of the attributes of the technology. Ability to mail, pick up at drive through, distribute without refrigeration to improve access. Phase1/2 completed in adults and children as young as 9 months (first in world) vaccinating for measles and rubella in Africa. (data available in 1st qtr 2023) Phase 1 completed in seasonal flu in adults showing equal and better immunogenicity as compared to IM injection. Phase 2 therapeutic for warts begins in January 2023. Additional vaccine and drug development work and trials underway and expected to begin soon. Company partners include large pharma, private pharma, foundations/agencies. Series A completed Nov. 2022.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Measles Rubella vaccination, Therapy for Warts
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Placeholder Photo
Micron Biomedical, Inc.